A Single-blind, Multi-center, Randomized, Active-controlled, Parallel Group, Phase II Study to Evaluate the Safety and Immunogenicity of Intramuscular Three Injections With LBVE(Multivalent Pneumococcal Conjugate Vaccine) Compared to Prevnar13 in Healthy Infants
Phase of Trial: Phase II
Latest Information Update: 23 Aug 2019
Price : $35 *
At a glance
- Drugs LBVE 013 (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate
- Indications Pneumococcal infections
- Focus Pharmacodynamics
- Sponsors LG Chem
- 21 Aug 2019 Status changed from active, no longer recruiting to completed.
- 04 Oct 2018 Planned End Date changed from 1 Mar 2019 to 30 Mar 2019.
- 04 Oct 2018 Status changed from not yet recruiting to active, no longer recruiting.